SLC26A9 in airways and intestine: secretion or absorption?

Karl Kunzelmann(University of Regensburg), Rainer Schreiber(University of Regensburg), Ursula Seidler(Medizinische Hochschule Hannover), Jiraporn Ousingsawat(University of Regensburg), Raquel Centeio(University of Lisbon), Khaoula Talbi(University of Regensburg)

Channels

March 3, 2023

10.1080/19336950.2023.2186434

Cited by 9

Related Papers

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

|New England Journal of Medicine|2016|1.8k

Probiotic Escherichia coli Nissle 1917 Inhibits Leaky Gut by Enhancing Mucosal Integrity

|PLoS ONE|2007|478

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

|The Lancet|2021|452

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

|The Lancet|2017|449

Intestinal Secretory Defects and Dwarfism in Mice Lacking cGMP-Dependent Protein Kinase II

|Science|1996|409